These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Auranofin (Ridaura). Med Lett Drugs Ther; 1985 Oct; 27(699):89-90. PubMed ID: 3932827 [No Abstract] [Full Text] [Related]
44. [Long-term tolerance of oral gold therapy in rheumatoid arthritis. Frequency and intensity of undesirable side effects]. Goebel KM; Storck U Schweiz Med Wochenschr; 1985 Dec; 115(49):1775-7. PubMed ID: 3937234 [TBL] [Abstract][Full Text] [Related]
45. Auranofin versus penicillamine in rheumatoid arthritis. One-year results from a prospective clinical investigation. Manthorpe R; Hørbov S; Sylvest J; Vinterberg H Scand J Rheumatol; 1986; 15(1):13-22. PubMed ID: 3083505 [TBL] [Abstract][Full Text] [Related]
46. The effects of auranofin and parenteral gold in the treatment of rheumatoid arthritis: an X-ray analysis. Larsen A; Horton J; Howland C Clin Rheumatol; 1984 Mar; 3 Suppl 1():97-104. PubMed ID: 6432419 [TBL] [Abstract][Full Text] [Related]
48. Auranofin: bane or bonanza for the nonrheumatologist. Kaplan H Am J Med; 1983 Dec; 75(6A):145-51. PubMed ID: 6419598 [TBL] [Abstract][Full Text] [Related]
49. Oral gold therapy in a patient with rheumatoid arthritis and preexisting uremia. Graninger W; Seidl G; Kovarik J; Pinggera W; Smolen JS Arthritis Rheum; 1985 Jun; 28(6):710-2. PubMed ID: 3924061 [No Abstract] [Full Text] [Related]
50. Longterm experience with oral gold in rheumatoid arthritis and psoriatic arthritis. Dequeker J; Verdickt W; Gevers G; Vanschoubroek K Clin Rheumatol; 1984 Mar; 3 Suppl 1():67-74. PubMed ID: 6432416 [TBL] [Abstract][Full Text] [Related]
51. Auranofin: 1 mg or 9 mg? The search for the appropriate dose. Calin A; Saunders D; Bennett R; Jacox R; Kaplan D; O'Brien W; Paulus HE; Roth S; Weiss T J Rheumatol Suppl; 1982; 8():146-8. PubMed ID: 6813476 [No Abstract] [Full Text] [Related]
52. Auranofin treatment for adult rheumatoid arthritis. Comparison of 2 mg and 6 mg daily dose. Bernhard GC J Rheumatol Suppl; 1982; 8():149-53. PubMed ID: 6813477 [TBL] [Abstract][Full Text] [Related]
54. [Multicenter double-blind comparison of auranofin and Tauredon]. Kaik B; Bröll H Wien Klin Wochenschr Suppl; 1984; 156():33-40. PubMed ID: 6442055 [TBL] [Abstract][Full Text] [Related]
55. Roentgenographic findings during auranofin treatment. Gofton JP; O'Brien W Am J Med; 1983 Dec; 75(6A):142-4. PubMed ID: 6419597 [TBL] [Abstract][Full Text] [Related]
56. Oral gold therapy with auranofin (SK&F 39162). A multicenter open study in patients with rheumatoid arthritis. Bandilla K; Gross D; Gross W; Herrlinger JD; Kriegel W; Müller W; Siegmeth W; Tausch G; Thumb N; Wagenhäuser FJ J Rheumatol Suppl; 1982; 8():154-9. PubMed ID: 6813478 [TBL] [Abstract][Full Text] [Related]
57. Auranofin: dose-related risk to benefit. Weiss TE Am J Med; 1983 Dec; 75(6A):128-32. PubMed ID: 6419594 [TBL] [Abstract][Full Text] [Related]
58. Effect of auranofin dose regimen change upon cell-associated gold in rheumatoid arthritic patients. Walz DT; Griswold DE; DiMartino MJ; Bumbier EE J Rheumatol; 1981; 8(5):829-32. PubMed ID: 6796684 [TBL] [Abstract][Full Text] [Related]
59. [Efficacy of therapy with triethylphosphine gold in a case of Felty's syndrome]. Fossaluzza V; Tosato F; Rossi P Clin Ter; 1986 Jun; 117(6):521-3. PubMed ID: 3091311 [No Abstract] [Full Text] [Related]